Skip to main content

Table 1 Characteristics of the literatures included in the meta-analysis

From: Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis

Author

Year

Content

Country

Sample (PB/PF)

Age

Intervene

Pin Zhang [24]

2016

Full text

China

92 (48/44)

24–73

Cb + P

Maria Cristina Aguilar Martinez [14]

2015

Abstract

America

61 (30/31)

47

DDP + P + D

Andreas Schneeweiss [9]

2019

Full text

Germany

1906 (961/945)

48

P + M + Cb

Oleg Gluz [15]

2018

Full text

America

336 (182/154)

50

Cb + P

Nadine Tung [25]

2020

Full text

Israeli

117 (60/57)

24–73

DDP

Madoka Iwase [16]

2020

Full text

Japan

179 (88/91)

NR

Cb + P + CEF

Chen Yanyu [22]

2021

Full text

China

84 (42/42)

37–66/36–68

Cb + P

Ke Da Yu [8]

2022

Full text

China

647 (325/322)

51

Cb + P

Andrew Tutt [26]

2018

Full text

England

376 (188/188)

NR

Cb

Yang Pan [23]

2019

Full text

China

48 (24/24)

42.41 ± 9.20/43.05 ± 9.41

Cb + P

Ingrid A Mayer [10]

2021

Full text

America

308 (148/160)

27–72/26–76

Cb/DDP

Sibylle Loibl [13]

2019

Full text

America

634 (476/158)

 ≥ 18

Cb + P

  1. NR, not reported; DDP, cis-platinum; D, doxorubicin; Cb, carboplatin; P, paclitaxel; M, myocet; CEF, cyclophosphamide + epirubicin + 5-fluorouracil